Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (TDOC) Form 144 shows an insider sale notice for 5,867 common shares, with an aggregate market value of $44,502.95, reported for an approximate sale date of 09/02/2025 on the NYSE. The shares were acquired by restricted stock vesting on 08/29/2025 and are being sold as compensation. The filer also reported a prior sale of 5,808 shares on 06/02/2025 for gross proceeds of $39,842.88. Outstanding shares are listed as 176,690,662, indicating the disclosed transactions represent a very small fraction of total shares.
Form 144 notice for Teladoc Health, Inc. (TDOC) shows a proposed sale of 12,846 common shares with an aggregate market value of $97,440.77 and an approximate sale date of 09/02/2025 on the NYSE. The filing reports the shares were acquired on 08/29/2025 through restricted stock vesting from the issuer and the payment nature is listed as compensation, indicating these are insider-awarded shares becoming eligible for sale.
The filing also discloses a sale by Mala Murthy of 13,856 shares on 06/02/2025 with gross proceeds of $95,052.16. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer. Shares outstanding are reported as 176,690,662.
TDOC Q2 2025 10-Q highlights:
- Revenue slipped 1.6 % YoY to $631.9 m; six-month revenue down 2.1 % to $1.26 bn. U.S. contributed 82 % of sales.
- Losses narrowed sharply. Q2 net loss was $32.7 m (-$0.19/sh) versus -$837.7 m (-$4.92/sh) a year ago, mainly because 2024 contained a $790 m goodwill charge. YTD loss is -$125.7 m (-$0.72/sh) versus -$919.6 m.
- Operating efficiency improved: EBITDA ex-items rose to $69.3 m vs. $89.5 m LY but YTD cash from ops increased to $107.4 m (+10 %). Advertising & marketing trimmed 1.6 %.
- Balance-sheet shifts: Cash fell to $679.6 m from $1.30 bn after $550.6 m retirement of 2025 convertible notes. Only $1 bn 1.25 % 2027 notes remain outstanding. Equity slipped 4.6 % to $1.42 bn; debt-to-equity now 0.70x.
- Intangibles & goodwill: New $59.1 m goodwill from Catapult Health was fully impaired, bringing total YTD impairment to the same amount versus $790 m LY. Intangibles amortization was $88.7 m for the quarter.
- Segment view: Integrated Care revenue +3.7 % YoY while BetterHelp -9.3 %. Integrated Care generated $57.5 m Adjusted EBITDA; BetterHelp $11.9 m.
- Liquidity backstop: On 17 Jul 2025 company executed a new five-year $300 m secured revolving credit facility with variable SOFR+2.75–3.25 % pricing.
Key takeaways: Profitability metrics and cash generation improved despite modest top-line softness, but cash reserves contracted materially after note redemptions and goodwill impairments continue to weigh on equity.
Form 4 snapshot: Teladoc Health, Inc. (TDOC) disclosed that director Jason Eric Evans converted restricted stock units (RSUs) into 1,016 shares of common stock on 20 June 2025. The transaction was coded “M,” indicating the exercise or conversion of a derivative security.
Following the transaction, Evans’ direct holdings in TDOC increased to 7,113 shares. His remaining unvested/undelivered derivative position stands at 5,082 RSUs. The RSUs originated from a 20 September 2023 grant of 12,195 units that vest one-third after one year and the balance in eight equal quarterly instalments.
No sale of shares was reported and no cash price was listed, implying a cost-free share settlement typical of RSU conversions. The filing contains no information on TDOC’s current operational performance, earnings, or other corporate events.
In sum, the Form 4 records a routine equity settlement that modestly increases insider share ownership but does not represent a market-moving development for Teladoc Health.